Analyst Marc Goodman of Leerink Partners reiterated a Buy rating on Kalaris Therapeutics (KLRS – Research Report), retaining the price target of $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Marc Goodman’s rating is based on several factors that highlight the potential of Kalaris Therapeutics. The company has made significant progress with its Phase 1 trial of TH103, a promising long-acting anti-VEGF agent for treating neovascular age-related macular degeneration. This trial is advancing as expected, and the anticipated safety and pharmacokinetic data set to be released in the fourth quarter of 2025 could provide further validation of the drug’s potential.
Additionally, Kalaris Therapeutics’ financial position is strengthened by the merger with AlloVir, which has resulted in a robust cash reserve of $101 million. This financial stability supports the company’s ongoing research and development efforts. Given these developments, Goodman maintains a positive outlook on the company’s future performance, justifying the Buy rating.
KLRS’s price has also changed dramatically for the past six months – from $0.559 to $3.250, which is a 481.40% increase.